Kamińska Joanna, Dymicka-Piekarska Violetta, Chrzanowski Robert, Sawicki Karol, Milewska Anna J, Zińczuk Justyna, Tylicka Marzena, Jadeszko Marek, Mariak Zenon, Kratz Ewa M, Matowicka-Karna Joanna, Kornhuber Johannes, Lewczuk Piotr, Koper-Lenkiewicz Olga M
Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Białystok, 15-269, Poland.
Department of Neurosurgery, Clinical Hospital of the Medical University of Białystok, Białystok, 15-276, Poland.
J Inflamm Res. 2021 Nov 23;14:6103-6114. doi: 10.2147/JIR.S335618. eCollection 2021.
Studies conducted so far have focused mainly on the assessment of IL-6 levels in patients with ruptured brain aneurysms. Carrying out detailed studies in patients with un-ruptured brain aneurysms (UIA) would be extremely important, as it would answer the question of whether IL-6 plays also a role in primary aneurysm formation and growth.
IL-6, S100, NSE, and albumin concentrations in 67 UIA patients and 17 individuals without vascular lesions in the brain were tested using in vitro diagnostic immunoassays according to the manufacturers' instructions. IL-6 Quotient was calculated by dividing cerebrospinal fluid (CSF) IL-6 by serum IL-6.
We showed that IL-6 Quotient was significantly higher in UIA patients (1.78) compared to the control group (0.87; p<0.001). Multivariate logistic regression analysis demonstrated that a growth in IL-6 Quotient increases the probability of UIA diagnosis. In UIA patients CSF IL-6 concentration was significantly higher (4.55 pg/ml) compared to the serum concentration (2.39 pg/ml; p<0.001). In both the study and control group, the blood-brain barrier was intact, thus the CSF-blood gradient of the IL-6 concentration in UIA patients was likely to be the expression of local synthesis of the cytokine within the central nervous system. Patients with multiple brain aneurysms had significantly higher CSF IL-6 levels (5.08 pg/ml) compared to individuals with a single aneurysm (4.14 pg/ml; p=0.0227).
This totality of the may suggest IL-6 as a biomarker for UIA formation; however, further studies are needed to unequivocally confirm clinical application of IL-6 concentration evaluation.
迄今为止开展的研究主要集中在对脑动脉瘤破裂患者白细胞介素-6（IL-6）水平的评估上。对未破裂脑动脉瘤（UIA）患者进行详细研究极为重要，因为这将回答IL-6是否在动脉瘤的原发性形成和生长中也起作用这一问题。
根据制造商的说明，使用体外诊断免疫测定法对67例UIA患者和17例无脑部血管病变的个体的IL-6、S100、神经元特异性烯醇化酶（NSE）和白蛋白浓度进行检测。通过将脑脊液（CSF）IL-6除以血清IL-6来计算IL-6商。
我们发现，与对照组（0.87；p<0.001）相比，UIA患者的IL-6商显著更高（1.78）。多因素逻辑回归分析表明，IL-6商的升高会增加UIA诊断的可能性。与血清浓度（2.39 pg/ml；p<0.001）相比，UIA患者的CSF IL-6浓度显著更高（4.55 pg/ml）。在研究组和对照组中，血脑屏障均完整，因此UIA患者中IL-6浓度的脑脊液-血液梯度可能是细胞因子在中枢神经系统内局部合成的表现。与单个动脉瘤患者（4.14 pg/ml；p=0.0227）相比，多发性脑动脉瘤患者的CSF IL-6水平显著更高（5.08 pg/ml）。
这一切可能提示IL-6作为UIA形成的生物标志物；然而，需要进一步研究以明确证实IL-6浓度评估的临床应用。
